New hope against deadly molds? early trial cut short

NCT ID NCT04240886

Terminated Disease control Sponsor: Basilea Pharmaceutica Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a drug called fosmanogepix in 21 adults with invasive mold infections (like Aspergillus or rare molds) who had few other options. The trial was stopped early, so we have limited data on how well it works or its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fosmanogepix (also called APX001)
What this could lead to: If successful, this could provide a new treatment option for people with hard-to-treat invasive mold infections who cannot use standard therapies.
What could go wrong: This was a small, early-phase trial that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aspergillosis COVID-19 fungal infectious disease fusariosis invasive aspergillosis Invasive Fungal Infections pulmonary aspergilloma scedosporiosis systemic mycosis Zygomycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE FUNGAL INFECTIONS

Contacts and locations

Locations

CHU UCL Namur - Mont- Godinne University Hospital - Intensive Care Unit

Yvoir, 5530, Belgium
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Duarte, California, 91010, United States
Cliniques Universitaires de Bruxelles Hôpital Erasme - Department of Infectious Diseases

Brussels, 1070, Belgium
Duke Department of Pharmacy/Investigational Drug Service (IDS)

Durham, North Carolina, 27710, United States
Duke Medicine Pavilion

Durham, North Carolina, 27710, United States
Duke University Medical Center (Duke South Clinic)

Durham, North Carolina, 27710, United States
Duke University Medical Center(Duke Hospital)

Durham, North Carolina, 27710, United States
IP Address : City of Hope Investigational Drug Services (IDS)

Duarte, California, 91010, United States
Klinikum Neuperlach, Klinik fur Hamatologie und Onkologie

München, Bavaria, 81737, Germany
Pharmacy

Haifa, 3109601, Israel
Pharmacy

Ramat Gan, 5262160, Israel
Rambam Medical Center

Haifa, 3109601, Israel
Sheba Medical Center, Tel Hashomer

Ramat Gan, 5262160, Israel
UZ Leuven - Department of Haematology

Leuven, 3000, Belgium
Universitätsmedizin der Johannes Gutenberg-Universität Mainz III

Mainz, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.